Wolfram syndrome, a rare autosomal recessive neurodegenerative disorder, was originally described as a combination of familial juvenile-onset diabetes mellitus and optic atrophy. It was later demonstrated that Wolfram syndrome patients were highly prone to psychiatric disorders. Mutations in exon 8 of the Wolfram syndrome gene account for 88% of the patients with Wolfram syndrome. To examine whether the gene responsible for causing Wolfram syndrome is involved in psychiatric disorders, we screened exon 8 of the Wolfram syndrome gene for mutations in 119 patients with schizophrenia, one patient with schizoaffective disorder, 12 patients with bipolar disorder and 15 patients with major depression, using sequence analysis. In Wolfram syndrome patients, this gene has been shown to have primarily nonsense or frameshift mutations, which would result in a premature truncation of the protein. None of the psychiatric patients screened in this study carried these types of mutations. We identified, however, 24 new variations whose significance remains to be determined. Molecular Psychiatry (2001) 6, 39-43.
Introduction
Wolfram syndrome (WS), also referred to as DIDMOAD (MIM222300) is a rare autosomal recessive disorder characterized by Diabetes Insipidus, juvenile Diabetes Mellitus, bilateral Optic Atrophy, sensoneural Deafness and acquired urinary tract abnormalities. [1] [2] [3] In WS homozygous patients, the pleiotropic effects caused by Wolframin mutations include psychiatric symptoms such as paranoid delusions, severe depression, attempted suicide and violent behavior. 4 An increase in psychiatric disorders was observed in 36 families with Wolfram syndrome. 5 We have reported that families of patients with WS have an increased risk for hospitalization in psychiatric institutions, pointing to a potential link of the WS gene to psychiatric disorders. 6 In that study, 10 of 11 relatives of patients with WS diagnosed with major depression requiring hospitalization, were carriers for the WS gene.
The gene causing WS has been recently identified and is predicted to code an ubiquitously expressed 100-kDa transmembrane protein. [7] [8] [9] In WS patients, the WS gene has been shown to have primarily nonsense or frameshift insertion/deletion mutations, which would result in a premature truncation of the protein.
A number of missense mutations, inframe deletions/insertions, a splice mutation and a microscopic deletion have also been described. [7] [8] [9] Eightyeight percent of these mutations are located within exon 8, which represents 68% of the WS gene coding sequence.
To assess the role of the WS gene in psychiatric disorders, we screened exon 8 for mutations in patients with schizophrenia, schizoaffective disorder, bipolar disorder and major depression. The aim of the study was to determine whether or not any of these patients carried a deletion or nonsense mutation in the WS gene. Although no such mutations were observed, we identified a number of new variations. Abbreviations: del = deletion, fs = frameshift, ter = termination, and ND = not determined.
a Amino acids are given in single-letter code.
Materials and methods

Subjects
Patient samples used were from the NIMH Cell Repository, Bethesda MD, USA; the Institute of Psychiatry (IoP), London, UK and the Departments of Biology and Psychiatry, Medical Faculty, University of Patras, Greece. The NIMH Cell Repository is a collection of US origin. These pedigrees have at least two affected biologically first-degree relatives. At least one member diagnosed with schizophrenia and a second member diagnosed with schizophrenia or schizoaffective disorder-depressive type were required for pedigree enrollment. All patients were interviewed using the Diagnostic Interview for Genetic Studies (DIGS) 10 and diagnosis was according to DSM-III-R. 11 We screened 89 probands from the NIMH collection. All of the probands met the criteria for schizophrenia.
Forty subjects from the IoP were collected between 1994 and 1999. All these subjects were of UK origin. Fifteen patients with schizophrenia from the IoP were receiving clozapine at the time of sampling, and were diagnosed by clinical interview according to DSM-III-R 11 or DSM-IV 12 criteria. Family history of psychosis
Molecular Psychiatry
was not recorded for this group. They may represent an 'atypical' group of patients since the licensing requirements of clozapine in the UK include the failure of a given patient to respond to typical neuroleptics. Ten patients with bipolar and 15 patients with unipolar disorder were diagnosed according to DSM-IV criteria using information from hospital case-notes, structured interviews (SADS-L, SCAN or a structured hospital discharge vignette) and all other available sources of information. Patients with schizoaffective disorder or a family history of schizophrenia were excluded from the bipolar disorder sample. The remaining patients were not selected with respect to family history of a psychiatric illness. Subjects from the Department of Psychiatry in Patras, Greece, belong to 18 unrelated pedigrees. These patients are of Greek origin. All patients were diagnosed using the Structured Clinical Interview for DSM-III-R. 13 There were 15 patients meeting DSM-IV criteria for schizophrenia, one for schizoaffective and two for bipolar I disorder. The origin and the diagnoses of the patients studied are listed in Table 1 . Patient samples from the UK and Greece were collected upon informed consent and [8AF 5Ј TGTAAAACGACGGCCAGT  CCTCGTTCCCACGTACCATC 3Ј; 8AR 5Ј CAGGAAA-CAGCTATGACCGTAGCAGTAGGTGCCCTTGA 3Ј; 8BF  5Ј  TGTAAAACGACGGCCAGTCCTGGTCG  TCCT  CAATGTCA 3Ј; 8BR 5Ј CAGGAAACAGCTATGACCA  TAGAACCAGCAGAACAGC 3Ј; 8CF 5Ј TGTAAAAC  GACGG CCAGTT GGTTCACGTCTCTGGAGCT 3Ј, 8DR  5Ј CAGGAAACAGCTATGACCGAACTTCTTGATGTG  GCAGG 3Ј; 8EF 5Ј TGTAAAAC GACGGCCAGTCT  GGATGCGCTGCCTCTACG 3Ј, 8FR 5Ј CAGGAAA  CAGCTATGAC CCCAAACAAA TAAGA AATGCT  3Ј] . 7 The M13 universal primer sequence was incorporated into the 5Ј terminus of primers for direct sequence analysis using the dideoxy terminator method. The amplicons were sequenced on an ABI 377 sequencer (Perkin Elmer, Foster City, CA, USA) according to the manufacturer's recommendations.
The frequency of the Ala602Val variation was assessed using Third Wave Technologies (TWT, Madison, WI, USA) Invader Assay.
14 Probe sets for each locus were designed and synthesized by TWT and the assay run according to the manufacturer's instructions.
Results/discussion
To investigate the role and nature of germline mutations of the WS gene, in familial and sporadic cases of psychiatric disorders, exon 8 of the WS gene, which hosts 88% of the mutations found in WS patients, was sequenced after amplification of patients' genomic DNA. None of the mutations found in Wolfram patients to date, summarized in Table 2 , were found in our group of psychiatric patients.
However, we identified 17 new independent missense mutations, which resulted in amino-acid substitutions (Table 3 ; Figure 1 ). An Ala602Val change was found in six schizophrenic patients from the NIMH collection out of 138 psychiatric patients tested. To assess the frequency of this variation, 168 individuals from the Coriell DNA Polymorphism Panel (M450PDR, http://locus.umdnj.edu/nigms/pdr.html) were studied. From 336 chromosomes, 10 revealed the C to T nucleotide change at position 1807 corresponding to a variation frequency of 3% against the 2% frequency observed in psychiatric patients. All other variations observed in this group of patients had a frequency of less than 1%, with the exception of change Arg818Cys which had a frequency of 2.2%. Two compound heterozygous were identified; a schizophrenic patient with a Gly786Ser and an Asp866Asn substitution, and a patient with major depression, showing an Ala559Thr change associated to an Ala586Thr substitution. The rare Ala559Thr variation has been recently reported in three bipolar and one unipolar patient 15 and was observed in one schizophrenic and one patient with major depression in our group of patients. Sequence analysis also revealed a number of silent variants.
Most of the mutations leading to WS are nonsense or frameshift insertion/deletion mutations predicting a premature truncation of the protein. None of these were found in this set of psychiatric patients, suggesting that the genetic contribution of these types of mutation of the WS gene in the disorders studied is expected to be rare. We have, however, identified a number of new variations. The significance of these new variants in the etiology of psychiatric disorders remains to be examined.
